Disclaimer
is resource is for informational purposes only, intended as a quick-reference tool based on the
cited source guideline(s), and should not be used as a substitute for the independent professional
judgment of healthcare providers. Practice guidelines are unable to account for every individual
variation among patients or take the place of clinician judgment, and the ultimate decision
concerning the propriety of any course of conduct must be made by healthcare providers aer
consideration of each individual patient situation. Guideline Central does not endorse any specific
guideline(s) or guideline recommendations and has not independently verified the accuracy hereof.
Any use of this resource or any other Guideline Central resources is strictly voluntary.
Source
Groh WJ, Bhakta D, Tomaselli GF, et al. 2022 HRS expert consensus statement
on evaluation and management of arrhythmic risk in neuromuscular disorders.
HeartRhythm. 2022;19(10):e61-e120. doi:10.1016/j.hrthm.2022.04.022
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2023 All rights reserved
HRSNMD04233b
GuidelineCentral.com
Abbreviations
AD, autosomal dominant; AF, atrial fibrillation; AFL, atrial flutter; AR, autosomal
recessive; AV, atrioventricular; BMD, Becker muscular dystrophy; BPM, beats per minute;
CIED, cardiovascular implantable electronic device; CM, cardiomyopathy; CMR, cardiac
magnetic resonance imaging ; COR, class of recommendation; CRM, cardiac rhythm
management; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization
therapy with defibrillator; CRT-P, cardiac resynchronization therapy with pacemaker;
DM, myotonic dystrophy; DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy
type 2; DMD, Duchenne muscular dystrophy; DMPK, myotonic dystrophy protein
kinase; DUX4, double homeobox 4; ECG, electrocardiogram; EDMD, Emery-Dreifuss
muscular dystrophy; EDMD1, Emery-Dreifuss muscular dystrophy type 1; EDMD2,
Emery-Dreifuss muscular dystrophy type 2; EDMD3, Emery-Dreifuss muscular dystrophy
type 3; EP, electrophysiological; FA, Friedreich ataxia; FSHD, facioscapulohumeral
muscular dystrophy; GDMT, guideline-directed medical therapy; HCM, hypertrophic
cardiomyopathy; ICD, implantable cardioverter-defibrillator; LBBB, le bundle branch
block; LGMD, limb-girdle muscular dystrophy; LGMD1B, limb-girdle muscular
dystrophy type 1B; LGMD2, limb-girdle muscular dystrophy type 2; LOE, level of
evidence; LVEF, le ventricular ejection fraction; mtDNA, mitochondrial DNA;
NMD, neuromuscular disorder; NYHA, New York Heart Association; PPM, permanent
pacemaker; RBBB, right bundle branch block; RCT, randomized controlled trial; RV,
right ventricular; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular
tachycardia; XL, X-linked; ZNF9, zinc finger 9
